Moshe C Ornstein (Moshe Ornstein)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Topics

Replacement Therapy

Prognostic Factors

Top Venues

Journal for immunotherapy of cancer

JCO oncology practice

Current oncology (Toronto, Ont.)

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Moshe C Ornstein, Lisa C Rosenblatt, Xin Yin, Viviana Del Tejo, Sarah B Guttenplan, Flavia Ejzykowicz, Kathleen Beusterien, Oliver Will, deMauri S Mackie, Grace Skiles, Marc DeCongelio
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment. Patient preference and adherence 18 (2024)
Moshe C Ornstein, Lisa C Rosenblatt, Xin Yin, Viviana Del Tejo, Sarah B Guttenplan, Flavia Ejzykowicz, Kathleen Beusterien, Oliver Will, deMauri S Mackie, Grace Skiles, Marc DeCongelio
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment. Patient preference and adherence 18 (2024)
Ramsha Ahmed, Moshe C Ornstein
Targeting HIF-2 Alpha in Renal Cell Carcinoma. Current treatment options in oncology (2023)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet Asim Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David Einstein, Paul J Catalano, Hans Hammers
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for immunotherapy of cancer 11 (3) (2023)
Michael B Atkins, Opeyemi A Jagede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark N Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael E Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David J Einstein, Paul J Catalano, Hans Hammers
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Alice Tzeng, Tony H Tzeng, Moshe C Ornstein
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. Journal for immunotherapy of cancer 9 (10) (2022)
Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, Matthew Kyle Labriola, Jennifer Tran, Konstantin H Dragnev, Laura J Tafe, Farshid Dayyani, Rajan T Gupta, Shannon McCall, Daniel J George, Sean T Glenn, Mary K Nesline, Saby George, Matthew Zibelman, Carl Morrison, Moshe C Ornstein, Tian Zhang
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. Journal for immunotherapy of cancer 10 (10) (2022)
Landon C Brown, Kunal Desai, Wei Wei, Emily N Kinsey, Chester Kao, Daniel J George, Brian I Rini, Moshe C Ornstein, Tian Zhang
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for immunotherapy of cancer 9 (9) (2022)
Moshe C Ornstein
Moving the Needle Toward Improved Survival in Metastatic Prostate Cancer. JCO oncology practice (2021)
Jennifer Tran, Moshe C Ornstein
Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO oncology practice (2021)
Scott J Dawsey, Steven C Campbell, Moshe C Ornstein
Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. Current oncology (Toronto, Ont.) 28 (3) (2021)
Kunal B Desai, Landon C Brown, Wei Wei, Matthew D Tucker, Chester Kao, Emily Kinsey, Brian Rini, Kathryn E Beckermann, Tian Zhang, Moshe C Ornstein
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted oncology 16 (5) (2021)
Scott J Dawsey, Moshe C Ornstein
Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. Current oncology (Toronto, Ont.) 28 (6) (2021)
Iris Y Sheng, Moshe C Ornstein
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date. Cancer management and research 12 (2020)
Iris Y Sheng, Megan Kruse, Kathryn M Leininger, Moshe C Ornstein
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). Case reports in oncological medicine 2019 (2019)
Moshe C Ornstein, Laura S Wood, Brian P Hobbs, Kimberly D Allman, Allison Martin, Michael Bevan, Timothy D Gilligan, Jorge A Garcia, Brian I Rini
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. Journal for immunotherapy of cancer 7 (1) (2019)